Format

Send to

Choose Destination
Cancer Causes Control. 2016 Jun;27(6):831-5. doi: 10.1007/s10552-016-0757-y. Epub 2016 May 4.

A prospective study of autoantibodies to Ezrin and pancreatic cancer risk.

Sun Y1,2, Wu J1, Cai H1, Wang S1, Liu Q1,3, Blot WJ1,4, Shu XO1, Cai Q5.

Author information

1
Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, 1161 21st Avenue South, Nashville, TN, 37232, USA.
2
Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China.
3
West China School of Public Health, Sichuan University, Chengdu, Sichuan, China.
4
International Epidemiology Institute, Rockville, MD, USA.
5
Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, 1161 21st Avenue South, Nashville, TN, 37232, USA. qiuyin.cai@vanderbilt.edu.

Abstract

PURPOSE:

No biomarker is available for pancreatic cancer early detection, but a small prospective European study involving 16 cases and 32 controls raised the possibility that anti-Ezrin autoantibodies may be associated with risk of pancreatic cancer. We aimed to validate this finding in a case-control study nested within a prospective study in the USA.

METHODS:

Levels of anti-Ezrin autoantibodies were examined using ELISA in pre-diagnostic plasma samples of 73 cases and 145 matched controls. Paired t test and paired signed rank tests were used to determine the difference between two groups, and conditional logistic regression was used to evaluate the association between anti-Ezrin autoantibody levels and risk of developing pancreatic cancer.

RESULTS:

No association was found between levels of anti-Ezrin plasma autoantibodies and subsequent risk of developing pancreatic cancer.

CONCLUSION:

Anti-Ezrin autoantibodies did not appear to be useful as a plasma biomarker for early detection of pancreatic cancer.

KEYWORDS:

Autoantibodies; Ezrin; Pancreatic cancer risk; Prospective study

PMID:
27146838
PMCID:
PMC4970458
DOI:
10.1007/s10552-016-0757-y
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center